Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer

Fig. 2

Indirect comparisons of toxicities: modified FOLFIRINOX vs. GEM-NAB. Data presented as odds ratio (OR) with 95% confidence interval (CI); the 95% confidence interval that did not contain the value of 1 represents as statistical significance. Statistically significant comparisons of toxicities between other treatments were also demonstrated

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us